A method for damaged viable disc regeneration has the steps of identifying the damaged viable disc and inserting a cannula via Kambin's Triangle to an edge of an outer annulus of the disc; introducing a trocar into the cannula and penetrating the trocar into a central region of nucleus pulposus; removing a tissue biopsy sample from the nucleus pulposus for pathology and removing additional degenerative tissue from the central region to create a void or space; withdrawing the trocar from the cannula and inserting a needle into the cannula to the void or space; and injecting a regenerative disc material through the needle into the void or space to repair the damaged disc.

A method for damaged viable disc regeneration has the steps of identifying the damaged viable disc and inserting a cannula via Kambin's Triangle to an edge of an outer annulus of the disc; introducing a trocar into the cannula and penetrating the trocar into a central region of nucleus pulposus; removing a tissue biopsy sample from the nucleus pulposus for pathology and removing additional degenerative tissue from the central region to create a void or space; withdrawing the trocar from the cannula and inserting a needle into the cannula to the void or space; and injecting a regenerative disc material through the needle into the void or space to repair the damaged disc.

Disclosed herein are stable live-cell compositions comprising a plurality of spheroids derived from neural progenitor cells and methods of making the spheroids. Also disclosed herein are methods of treating a neuronal disorder or disease.

A method of preserving a donor organ for transplantation may include flushing the donor organ with flush solution comprising itaconate and storing the flushed donor organ. The flush solution may comprise dimethyl itaconate (DI) in an amount greater than or equal to 0.1 mM and less than or equal to 0.75 mM. Following removal from storage, the donor organ may be perfused using an ex vivo organ perfusion (EVOP) process. The perfusate may also include itaconate.

A method of preserving a donor organ for transplantation may include flushing the donor organ with flush solution comprising itaconate and storing the flushed donor organ. The flush solution may comprise dimethyl itaconate (DI) in an amount greater than or equal to 0.1 mM and less than or equal to 0.75 mM. Following removal from storage, the donor organ may be perfused using an ex vivo organ perfusion (EVOP) process. The perfusate may also include itaconate.

A method of making infused bone fibers employs the following steps: cutting or shaving whole bone into bone fibers, washing the bone fibers, demineralizing or decalcifying at least partially the whole bone or bone fibers and infusing the bone fibers with a supernatant of biologic material or a polyampholyte cryoprotectant or a combination of both to create infused bone fibers. The step of infusing includes exposing the bone fibers to a negative pressure or vacuum to draw the supernatant and/or the polyampholyte cryoprotectant into the bone fibers, or alternatively, exposing the demineralized whole bone to a positive pressure to drive the supernatant and/or the polyampholyte cryoprotectant into the bone. The resultant method creates an infused bone grafting composition having bone fibers taken from whole bone, demineralized or decalcified at least partially and infused with one or more of a supernatant of biologic material or a polyampholyte cryoprotectant or both.

A cell culture vessel for culturing a cell in an interior thereof, has a feature that a width of a bottom surface is equal to or larger than a height of a side surface. The cell culture vessel includes a flow path for supplying a fluid into the interior, and the interior is able to be closed.

A cell culture vessel for culturing a cell in an interior thereof, has a feature that a width of a bottom surface is equal to or larger than a height of a side surface. The cell culture vessel includes a flow path for supplying a fluid into the interior, and the interior is able to be closed.

A system and m ethos for vitrification by transitioning tissues into a vitreous state at cryogenic temperatures and protecting them from ice crystal damage using high concentrations of cryoprotectant agents (CPAs). This system balances penetration and reducing cell toxicity. The system and method use a simulation-based optimization approach developed by combining computational modeling with microcomputed tomography imaging to predict three-dimensional CPA distributions within tissues over time accurately. In one embodiment, CPA exposure time was minimized, resulting in 85% viability in 4-ml meniscal specimens, 70% in 10-ml whole knee menisci, and 85% in 15-ml whole TMJ menisci (i.e., TMJ disc) post-vitrification, outperforming slow-freezing methods (20%-40%). Vitreous meniscus grafts demonstrated clinical-level viability (70%), closely resembling the material properties of native tissues, with long-term availability for transplantation.

A system and m ethos for vitrification by transitioning tissues into a vitreous state at cryogenic temperatures and protecting them from ice crystal damage using high concentrations of cryoprotectant agents (CPAs). This system balances penetration and reducing cell toxicity. The system and method use a simulation-based optimization approach developed by combining computational modeling with microcomputed tomography imaging to predict three-dimensional CPA distributions within tissues over time accurately. In one embodiment, CPA exposure time was minimized, resulting in 85% viability in 4-ml meniscal specimens, 70% in 10-ml whole knee menisci, and 85% in 15-ml whole TMJ menisci (i.e., TMJ disc) post-vitrification, outperforming slow-freezing methods (20%-40%). Vitreous meniscus grafts demonstrated clinical-level viability (70%), closely resembling the material properties of native tissues, with long-term availability for transplantation.